Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
19 Dezembro 2023 - 9:00AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN
PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of December 2023.
Commission File Number: 001-39071
ADC Therapeutics SA
(Exact name of registrant as specified in its
charter)
Biopôle
Route de la Corniche
3B
1066 Epalinges
Switzerland
(Address of principal
executive office)
Indicate by check
mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
INFORMATION CONTAINED IN THIS REPORT ON FORM
6-K
On December 5, 2023, ADC Therapeutics SA (the “Company”)
provided notice of termination under the Open Market Sales Agreement, dated June 4, 2021, between the Company and Jefferies LLC, relating
to its at-the-market offering program. The termination is effective as of December 19, 2023. Accordingly, the Company will not make any
further offer or sale of securities pursuant to the prospectus relating to the program. The Company has not sold any common shares under
the program.
INCORPORATION BY REFERENCE
This Report on Form 6-K shall be deemed to be incorporated
by reference into the registration statement on Form F-3 (Registration No. 333-270570) of ADC Therapeutics SA and to be a part thereof
from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
ADC Therapeutics SA |
Date: December 19, 2023 |
|
|
|
|
By: |
/s/ Peter J. Graham |
|
Name: |
Peter J. Graham |
|
Title: |
Chief Legal Officer |
ADC Therapeutics (NYSE:ADCT)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
ADC Therapeutics (NYSE:ADCT)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024